Role of Obesity in Asthma Control, the Obesity-Asthma Phenotype

Table 3

Studies of responses to therapy in overweight or obese asthmatics compared to normal BMI.

Study	Asthma therapy	Number of subjects	Results
Farah et al., 2011 [36]	Fluticasone/salmeterol	49	Similar improvements in asthma control, spirometry, airway inflammation, and airway hyperresponsiveness across BMI groups
Sutherland et al., 2010 [46]	Fluticasone, montelukast	1052	Fluticasone greater improvement across all BMI categories when compared to montelukast
Sutherland et al., 2008 [37]	Glucocorticoids	45	Decreased in vitro response to glucocorticoids in obese asthmatics
Boulet and Franssen 2007 [35]	Fluticasone with or without salmeterol	1242	Fluticasone with salmeterol resulted in improved asthma control in both groups compared to fluticasone alone but overall decreased effectiveness with both regimens in obese patients
Dixon et al., 2006 [38]	Theophylline, montelukast, placebo	488	Increased risk of exacerbations in obese subjects treated with theophylline but no difference in montelukast treatment groups
Peters-Golden et al., 2006 [34]	Beclomethasone, montelukast, placebo	3073	Less improvement in asthma control days with inhaled corticosteroid with increasing BMI, no difference with montelukast